RT Journal Article SR Electronic T1 Multifocal pattern electroretinography for the detection of neural loss in eyes with permanent temporal hemianopia or quadrantanopia from chiasmal compression JF British Journal of Ophthalmology JO Br J Ophthalmol FD BMJ Publishing Group Ltd. SP 104 OP 109 DO 10.1136/bjo.2010.199661 VO 96 IS 1 A1 Mário Luiz Ribeiro Monteiro A1 Kenzo Hokazono A1 Leonardo Provetti Cunha A1 Maria Kiyoko Oyamada YR 2012 UL http://bjo.bmj.com/content/96/1/104.abstract AB Aims To evaluate the ability of multifocal transient pattern electroretinography (mfPERG) to detect neural loss and assess the relationship between mfPERG and visual-field (VF) loss in eyes with chiasmal compression.Methods 23 eyes from 23 patients with temporal VF defects and band atrophy of the optic nerve and 21 controls underwent standard automated perimetry and mfPERG using a stimulus pattern of 19 rectangles, each consisting of 12 squares. The response was determined for the central rectangle, for the nasal and temporal hemifields (eight rectangles each) and for each quadrant (three rectangles) in both patients and controls. Comparisons were made using variance analysis. Correlations between VF and mfPERG measurements were verified by linear regression analysis.Results Mean±SD mfPERG amplitudes from the temporal hemifield (0.50±0.17 and 0.62±0.32) and temporal quadrants (superior 0.42±0.21 and 0.52±0.35, inferior 0.51±0.23 and 0.74±0.40) were significantly lower in eyes with band atrophy than in controls (0.78±0.24, 0.89±0.28, 0.73±0.26, 0.96±0.36, 0.79±0.26 and 0.91±0.31, respectively). No significant difference was observed in nasal hemifield measurements. Significant correlations (0.36–0.73) were found between VF relative sensitivity and mfPERG amplitude in different VF sectors.Conclusions mfPERG amplitude measurements clearly differentiate eyes with temporal VF defect from controls. The good correlation between mfPERG amplitudes and the severity of VF defect suggests that mfPERG may be used as an indicator of ganglion cell dysfunction.Clinical trial registration number ClinicalTrial.gov identifier number NCT00553761.